0
     

Report Added
Report already added
Artificial Intelligence ( AI ) in Drug Discovery Market by Offering (Software, Service), Technology (Machine Learning, Deep Learning), Application (Cardiovascular, Metabolic, Neurodegenerative), End User (Pharma, Biotech,CROs) - Global Forecasts ( 2022 - 2027 )

Artificial Intelligence ( AI ) in Drug Discovery Market by Offering (Software, Service), Technology (Machine Learning, Deep Learning), Application (Cardiovascular, Metabolic, Neurodegenerative), End User (Pharma, Biotech,CROs) - Global Forecasts ( 2022 - 2027 )

The Artificial intelligence/AI in drug discovery Market is projected to reach USD 4.0 billion by 2027 from USD 0.6 billion in 2022, at a CAGR of 45.7% during the forecast period. The growth of this market is primarily driven by factors such as the need to control drug discovery & development costs and reduce the overall time taken in this process, the rising adoption of cloud-based applications and services. On the other hand, the inadequate availability of skilled labor is key factor restraining the market growt at certain extent over the forecast period.

“Services segment is estimated to hold the major share in 2022 and also expected to grow at the highest over the forecast period”

On the basis of offering, the AI in drug discovery market is bifurcated into software and services. the services segment expected to account for the largest market share of the global AI in drug discovery services market in 2022, and expected to grow fastest CAGR during the forecast period. The advantages and benefits associated with these services and the strong demand for AI services among end users are the key factors for thegrowth of this segment.

“Machine learning technology segment accounted for the largest share of the global AI in drug discovery market”

On the basis of technology, the AI in drug discovery market is segmented into machine learning and other technologies. The machine learning segment accounted for the largest share of the global market in 2021 and expected to grow at the highest CAGR during the forecast period. High adoption of machine learning technology among CRO, pharmaceutical and biotechnology companies and capability of these technologies to extract insights from data sets, which helps accelerate the drug discovery process are some of the factors supporting the market growth of this segment.

“Pharmaceutical & biotechnology companies segment expectd to hold the largest share of the market in 2022”

On the basis of end user, the AI in drug discovery market is divided into pharmaceutical & biotechnology companies, CROs, and research centers and academic & government institutes. In 2021, the pharmaceutical & biotechnology companies segment accounted for the largest share of the AI in drug discovery market. On the other hand, research centers and academic & government institutes are expected to witness the highest CAGR during the forecast period. The strong demand for AI-based tools in making the entire drug discovery process more time and cost-efficient is the key growth factor of pharmaceutical and biotechnology end-user segment.

“North America to dominate the AI in drug discovery market in 2021”

The global AI in the drug discovery market is segmented into four major regions, namely, North America, Europe, APAC, and the Rest of the World. In 2021, North America accounted for the largest and the fastest-growing regional market for AI in drug discovery. North America, which comprises the US, Canada, and Mexico, forms the largest market for AI in drug discovery. These countries have been early adopters of AI technology in drug discovery and development. Presence of key established players, well-established pharmaceutical and biotechnology industry, and high focus on R&D & substantial investment are some of the major factors responsible for the large share and high growth rate of this market.

Breakdown of supply-side primary interviews, by company type, designation, and region:
• By Company Type: Tier 1 (31%), Tier 2 (28%), and Tier 3 (41%)
• By Designation: C-level (31%), Director-level (25%), and Others (44%)
• By Region: North America (45%), Europe (20%), Asia Pacific (28%), and RoW (7%)

Prominent players in this market are NVIDIA Corporation (US), Microsoft Corporation (US), Google (US), Exscientia (UK), Schrödinger (US), Atomwise, Inc. (US), BenevolentAI (UK), NuMedii (US), BERG LLC (US), Cloud Pharmaceuticals (US), Insilico Medicine (US), Cyclica (Canada), Deep Genomics (Canada), IBM (US), BIOAGE (US), Valo Health (US), Envisagenics (US), twoXAR (US), Owkin, Inc. (US), XtalPi (US), Verge Genomics (US), Biovista (US), Evaxion Biotech (Denmark), Iktos (France), Standigm (South Korea), and BenchSci (Canada). Players adopted organic as well as inorganic growth strategies such as product upgrades, collaborations, agreements, partnerships, and acquisitions to increase their offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.

Research Coverage
•The report studies the AI in drug discovery market based on offering, technology, application, end user, and region
•The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth
•The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders
•The report studies micro-markets with respect to their growth trends, prospects, and contributions to the total AI in drug discovery market
•The report forecasts the revenue of market segments with respect to five major regions

Key Benefits of Buying the Report:
The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the AI in drug discovery market and provides them information on key market drivers, restraints, challenges, and opportunities.
Table of Contents

1INTRODUCTION26
1.1OBJECTIVES OF THE STUDY26
1.2MARKET DEFINITION26
1.2.1ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: INCLUSIONS & EXCLUSIONS27
1.3MARKET SCOPE28
1.3.1MARKETS COVERED28
FIGURE 1ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY: MARKET SEGMENTATION28
1.3.2YEARS CONSIDERED FOR THE STUDY28
1.4CURRENCY29
1.5LIMITATIONS29
1.6STAKEHOLDERS29
1.7SUMMARY OF CHANGES30
2RESEARCH METHODOLOGY31
2.1RESEARCH DATA31
FIGURE 2RESEARCH DESIGN31
2.2SECONDARY SOURCES32
2.2.1KEY DATA FROM SECONDARY SOURCES33
2.3PRIMARY DATA33
2.3.1PRIMARY SOURCES34
2.3.2BREAKDOWN OF PRIMARY INTERVIEWS35
FIGURE 3BREAKDOWN OF PRIMARY INTERVIEWS: BY DEMAND SIDE, SUPPLY SIDE, DESIGNATION, AND REGION35
2.3.2.1Key industry insights35
2.4MARKET SIZE ESTIMATION36
FIGURE 4SUPPLY-SIDE MARKET ESTIMATION: REVENUE SHARE ANALYSIS37
FIGURE 5BOTTOM-UP APPROACH: END-USER SPENDING ON AI IN DRUG DISCOVERY38
TABLE 1FACTOR ANALYSIS40
FIGURE 6CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN THE AI IN DRUG DISCOVERY MARKET (2022–2027)40
FIGURE 7CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS41
FIGURE 8TOP-DOWN APPROACH41
2.5MARKET BREAKDOWN AND DATA TRIANGULATION42
FIGURE 9DATA TRIANGULATION METHODOLOGY42
TABLE 2MARKET SIZING ASSUMPTIONS43
2.6OVERALL STUDY ASSUMPTIONS43
2.7LIMITATIONS44
2.8RISK ASSESSMENT44
TABLE 3RISK ASSESSMENT: AI IN DRUG DISCOVERY MARKET44
3EXECUTIVE SUMMARY45
FIGURE 10ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2022 VS. 2027 (USD MILLION)45
FIGURE 11ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)46
FIGURE 12ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)46
FIGURE 13GEOGRAPHICAL SNAPSHOT OF THE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET47
4PREMIUM INSIGHTS48
4.1ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET OVERVIEW48
FIGURE 14GROWING NEED TO CONTROL DRUG DISCOVERY & DEVELOPMENT COSTS IS A KEY FACTOR DRIVING THE ADOPTION OF AI IN DRUG DISCOVERY SOLUTIONS48
4.2ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING (2021–2027)49
FIGURE 15SERVICES SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD49
4.3ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE & REGION (2021)50
FIGURE 16DEEP LEARNING SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 202150
4.4ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES51
FIGURE 17NORTH AMERICA IS THE FASTEST-GROWING REGIONAL MARKET FOR AI IN DRUG DISCOVERY51
5MARKET OVERVIEW52
5.1INTRODUCTION52
5.2MARKET DYNAMICS52
FIGURE 18ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES52
5.2.1MARKET DRIVERS53
5.2.1.1Growing number of cross-industry collaborations and partnerships53
TABLE 4INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS (2019−2021)53
5.2.1.2Growing need to control drug discovery & development costs and reduce time involved in drug development54
5.2.1.3Patent expiry of several drugs54
TABLE 5INDICATIVE LIST OF DRUGS LOSING PATENTS IN 202254
5.2.2MARKET RESTRAINTS55
5.2.2.1Shortage of AI workforce and ambiguous regulatory guidelines for medical software55
5.2.3MARKET OPPORTUNITIES55
5.2.3.1Growing biotechnology industry55
5.2.3.2Emerging markets56
5.2.3.3Focus on developing human-aware AI systems56
5.2.3.4Growth in the drugs and biologics market despite the COVID-19 pandemic56
5.2.4MARKET CHALLENGES56
5.2.4.1Limited availability of data sets56
5.3VALUE CHAIN ANALYSIS57
FIGURE 19AI IN DRUG DISCOVERY MARKET: VALUE CHAIN ANALYSIS (2021)57
5.4PORTER’S FIVE FORCES ANALYSIS58
TABLE 6AI IN DRUG DISCOVERY MARKET: PORTER’S FIVE FORCES ANALYSIS58
5.5ECOSYSTEM59
FIGURE 20AI IN DRUG DISCOVERY MARKET ECOSYSTEM59
5.6TECHNOLOGY ANALYSIS59
5.7PRICING ANALYSIS60
5.8BUSINESS MODELS60
FIGURE 21AI IN LIFE SCIENCES: BUSINESS MODELS61
FIGURE 22BENEFITS OF HYBRID BUSINESS MODELS61
FIGURE 23SPECIALIZATION OF AI COMPANIES OVER TIME62
5.9REGULATIONS63
5.10CONFERENCES AND WEBINARS63
5.11CASE STUDY ANALYSIS64
5.11.1CASE STUDY 164
5.11.2CASE STUDY 265
6ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING66
6.1INTRODUCTION67
TABLE 7ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)67
6.2SOFTWARE67
6.2.1BENEFITS OFFERED BY SOFTWARE IN DRUG DISCOVERY & STRONG DEMAND AMONG END USERS ARE DRIVING SEGMENT GROWTH67
TABLE 8ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY REGION, 2020–2027 (USD MILLION)68
TABLE 9NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION)68
TABLE 10EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION)68
TABLE 11APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION)69
6.3SERVICES69
6.3.1SERVICES SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD69
TABLE 12ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY REGION, 2020–2027 (USD MILLION)70
TABLE 13NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY, 2020–2027 (USD MILLION)70
TABLE 14EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY, 2020–2027 (USD MILLION)70
TABLE 15APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY, 2020–2027 (USD MILLION)71
7ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY72
7.1INTRODUCTION73
TABLE 16ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)73
7.2MACHINE LEARNING73
TABLE 17ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2020–2027 (USD MILLION)74
TABLE 18ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY REGION, 2020–2027 (USD MILLION)74
TABLE 19NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)74
TABLE 20EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)75
TABLE 21APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)75
7.2.1DEEP LEARNING75
7.2.1.1Deep learning accelerates the discovery process of life-saving drugs and precision medicine75
TABLE 22ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY REGION, 2020–2027 (USD MILLION)76
TABLE 23NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)76
TABLE 24EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)77
TABLE 25APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)77
7.2.2SUPERVISED LEARNING77
7.2.2.1Supervised learning can be applied in drug repositioning77
TABLE 26ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY REGION, 2020–2027 (USD MILLION)78
TABLE 27NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)78
TABLE 28EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)78
TABLE 29APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)79
7.2.3REINFORCEMENT LEARNING79
7.2.3.1Insilico Medicine is a pioneer in the application of reinforcement learning in drug discovery79
TABLE 30ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY REGION, 2020–2027 (USD MILLION)79
TABLE 31NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)80
TABLE 32EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)80
TABLE 33APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)80
7.2.4UNSUPERVISED LEARNING81
7.2.4.1Unsupervised learning can be more unpredictable than alternate models81
TABLE 34ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY REGION, 2020–2027 (USD MILLION)81
TABLE 35NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)81
TABLE 36EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)82
TABLE 37APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)82
7.2.5OTHER MACHINE LEARNING TECHNOLOGIES82
TABLE 38ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION)83
TABLE 39NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION)83
TABLE 40EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION)83
TABLE 41APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION)84
7.3OTHER TECHNOLOGIES84
TABLE 42ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION)85
TABLE 43NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION)85
TABLE 44EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION)85
TABLE 45APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION)86
8ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION87
8.1INTRODUCTION88
TABLE 46ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)88
8.2IMMUNO-ONCOLOGY88
8.2.1HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE CANCER DRUGS TO DRIVE SEGMENT GROWTH88
TABLE 47INDICATIVE LIST OF INITIATIVES IN IMMUNO-ONCOLOGY DRUG DEVELOPMENT89
TABLE 48ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY REGION, 2020–2027 (USD MILLION)89
TABLE 49NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)89
TABLE 50EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)90
TABLE 51APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)90
8.3NEURODEGENERATIVE DISEASES90
8.3.1AI IS BEING USED TO RESOLVE EXISTING CHALLENGES IN NEUROLOGICAL DISEASE DRUG DEVELOPMENT90
TABLE 52ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY REGION, 2020–2027 (USD MILLION)91
TABLE 53NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)91
TABLE 54EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)92
TABLE 55APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)92
8.4CARDIOVASCULAR DISEASES92
8.4.1RISING DEMAND FOR CVD DRUGS IS DRIVING SEGMENT GROWTH92
TABLE 56INDICATIVE LIST OF DEVELOPMENTS IN CARDIOVASCULAR DRUG DEVELOPMENT93
TABLE 57ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020–2027 (USD MILLION)93
TABLE 58NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)93
TABLE 59EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)94
TABLE 60APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)94
8.5METABOLIC DISEASES94
8.5.1ROLE OF AI IN UNCOVERING SMALL-MOLECULE THERAPIES IS DRIVING ITS ADOPTION IN THIS SEGMENT94
TABLE 61ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY REGION, 2020–2027 (USD MILLION)95
TABLE 62NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)95
TABLE 63EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)95
TABLE 64APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)96
8.6OTHER APPLICATIONS96
TABLE 65ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)96
TABLE 66NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)97
TABLE 67EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)97
TABLE 68APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)97
9ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER98
9.1INTRODUCTION99
TABLE 69ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)99
9.2PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES99
9.2.1RISING DEMAND FOR SOLUTIONS TO CUT TIME AND COSTS OF DRUG DEVELOPMENT HAS DRAWN END-USER ATTENTION TO AI99
TABLE 70INDICATIVE LIST OF DEVELOPMENTS RELATED TO THE USE OF AI IN THE PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY100
TABLE 71ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION)100
TABLE 72NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)101
TABLE 73EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)101
TABLE 74APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)101
9.3CONTRACT RESEARCH ORGANIZATIONS102
9.3.1GROWING TREND OF OUTSOURCING TO PROVIDE SIGNIFICANT OPPORTUNITIES FOR CONTRACT RESEARCH ORGANIZATIONS102
TABLE 75INDICATIVE LIST OF COLLABORATIONS WITH CROS102
TABLE 76ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020–2027 (USD MILLION)102
TABLE 77NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)103
TABLE 78EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)103
TABLE 79APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)103
9.4RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES104
9.4.1THIS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD104
TABLE 80INDICATIVE LIST OF RESEARCH COLLABORATIONS104
TABLE 81ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY REGION, 2020–2027 (USD MILLION)104
TABLE 82NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)105
TABLE 83EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)105
TABLE 84APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)105
10ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION106
10.1INTRODUCTION107
TABLE 85ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION, 2020–2027 (USD MILLION)107
10.2NORTH AMERICA107
FIGURE 24NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SNAPSHOT108
TABLE 86NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)109
TABLE 87NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)109
TABLE 88NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)109
TABLE 89NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)110
TABLE 90NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)110
10.2.1US110
10.2.1.1Strong economy and trend of early adoption of technologies are driving market growth in the US110
TABLE 91INDICATIVE LIST OF STRATEGIC DEVELOPMENTS IN THE US MARKET111
TABLE 92US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)111
TABLE 93US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)112
TABLE 94US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)112
TABLE 95US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)112
10.2.2CANADA113
10.2.2.1Growing research on AI technologies and emergence of new AI-based start-ups will support market growth in Canada113
TABLE 96CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)113
TABLE 97CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)114
TABLE 98CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)114
TABLE 99CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)114
10.2.3MEXICO115
10.2.3.1Government initiatives to support market growth in Mexico115
TABLE 100MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)115
TABLE 101MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)115
TABLE 102MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)116
TABLE 103MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)116
10.3EUROPE116
FIGURE 25EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SNAPSHOT117
TABLE 104EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)118
TABLE 105EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)118
TABLE 106EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)118
TABLE 107EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)119
TABLE 108EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)119
10.3.1UK119
10.3.1.1UK holds the largest share of the European market119
TABLE 109INDICATIVE LIST OF STRATEGIC DEVELOPMENTS IN THE UK120
TABLE 110UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)120
TABLE 111UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)121
TABLE 112UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)121
TABLE 113UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)121
10.3.2GERMANY122
10.3.2.1Government support and favorable training programs are key market drivers in Germany122
TABLE 114GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)122
TABLE 115GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)123
TABLE 116GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)123
TABLE 117GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)123
10.3.3FRANCE124
10.3.3.1Strong government support and favorable strategies & initiatives to drive market growth in France124
TABLE 118FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)124
TABLE 119FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)124
TABLE 120FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)125
TABLE 121FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)125
10.3.4ITALY125
10.3.4.1Presence of a strong pharmaceutical industry in Italy to drive market growth125
TABLE 122ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)126
TABLE 123ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)126
TABLE 124ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)126
TABLE 125ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)127
10.3.5REST OF EUROPE127
TABLE 126ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)127
TABLE 127ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)128
TABLE 128ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)128
TABLE 129ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)128
10.4ASIA PACIFIC129
TABLE 130APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)129
TABLE 131APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)129
TABLE 132APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)130
TABLE 133APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)130
TABLE 134APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)130
10.4.1JAPAN131
10.4.1.1Japan dominates the APAC market for AI in drug discovery131
TABLE 135JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)131
TABLE 136JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)132
TABLE 137JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)132
TABLE 138JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)132
10.4.2CHINA133
10.4.2.1Growing CMO market and cross-industry collaborations are factors responsible for market growth in China133
TABLE 139CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)133
TABLE 140CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)133
TABLE 141CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)134
TABLE 142CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)134
10.4.3INDIA134
10.4.3.1Steady adoption of AI technologies will drive market growth in India134
TABLE 143INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)135
TABLE 144INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)135
TABLE 145INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)135
TABLE 146INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)136
10.4.4REST OF ASIA PACIFIC136
TABLE 147ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)136
TABLE 148ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)137
TABLE 149ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)137
TABLE 150ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)137
10.5REST OF THE WORLD138
TABLE 151ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)138
TABLE 152ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)138
TABLE 153ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)139
TABLE 154ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)139
11COMPETITIVE LANDSCAPE140
11.1OVERVIEW140
11.2KEY PLAYER STRATEGIES/RIGHT TO WIN140
11.2.1OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE AI IN DRUG DISCOVERY MARKET140
11.3MARKET RANKING ANALYSIS141
TABLE 155AI IN DRUG DISCOVERY MARKET RANKING ANALYSIS, BY KEY PLAYER, 2021142
11.4COMPETITIVE BENCHMARKING143
TABLE 156AI IN DRUG DISCOVERY MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS143
TABLE 157AI IN DRUG DISCOVERY MARKET: APPLICATION FOOTPRINT OF KEY PLAYERS143
TABLE 158AI IN DRUG DISCOVERY MARKET: REGIONAL FOOTPRINT OF KEY PLAYERS144
11.5COMPETITIVE LEADERSHIP MAPPING144
11.5.1STARS144
11.5.2EMERGING LEADERS144
11.5.3PERVASIVE PLAYERS145
11.5.4PARTICIPANTS145
FIGURE 26AI IN DRUG DISCOVERY MARKET: GLOBAL COMPANY EVALUATION MATRIX, 2021145
11.6COMPETITIVE LEADERSHIP MAPPING – START-UPS/SMES146
11.6.1PROGRESSIVE COMPANIES146
11.6.2STARTING BLOCKS146
11.6.3RESPONSIVE COMPANIES146
11.6.4DYNAMIC COMPANIES146
FIGURE 27AI IN DRUG DISCOVERY MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2021147
11.7COMPETITIVE SITUATIONS AND TRENDS148
TABLE 159PRODUCT LAUNCHES148
TABLE 160DEALS148
12COMPANY PROFILES151
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *
12.1KEY PLAYERS151
12.1.1MICROSOFT151
TABLE 161MICROSOFT: BUSINESS OVERVIEW151
FIGURE 28MICROSOFT: COMPANY SNAPSHOT (2020)152
TABLE 162MICROSOFT: DEALS153
12.1.2NVIDIA155
TABLE 163NVIDIA: BUSINESS OVERVIEW155
FIGURE 29NVIDIA: COMPANY SNAPSHOT (2022)156
TABLE 164NVIDIA: EXPANSIONS157
TABLE 165NVIDIA: DEALS157
12.1.3EXSCIENTIA158
TABLE 166EXSCIENTIA: BUSINESS OVERVIEW158
FIGURE 30EXSCIENTIA: COMPANY SNAPSHOT (2021)158
12.1.4GOOGLE162
TABLE 167GOOGLE: BUSINESS OVERVIEW162
FIGURE 31GOOGLE: COMPANY SNAPSHOT (2021)163
12.1.5BENEVOLENTAI165
TABLE 168BENEVOLENTAI: BUSINESS OVERVIEW165
12.1.6NUMEDII, INC.167
TABLE 169NUMEDII: BUSINESS OVERVIEW167
12.1.7BERG, LLC169
TABLE 170BERG, LLC: BUSINESS OVERVIEW169
12.1.8ATOMWISE171
TABLE 171ATOMWISE: BUSINESS OVERVIEW171
12.1.9DEEP GENOMICS173
TABLE 172DEEP GENOMICS: BUSINESS OVERVIEW173
12.1.10INSILICO MEDICINE175
TABLE 173INSILICO MEDICINE: BUSINESS OVERVIEW175
12.1.11SCHRÖDINGER, INC.177
TABLE 174SCHRÖDINGER: BUSINESS OVERVIEW177
FIGURE 32SCHRÖDINGER: COMPANY SNAPSHOT (2021)178
12.1.12IBM181
TABLE 175IBM: BUSINESS OVERVIEW181
FIGURE 33IBM: COMPANY SNAPSHOT (2022)182
TABLE 176IBM: DEALS183
TABLE 177IBM: OTHER DEVELOPMENTS183
12.2OTHER PLAYERS184
12.2.1CYCLICA INC.184
12.2.2CLOUD PHARMACEUTICALS184
12.2.3BIOAGE185
12.2.4ENVISAGENICS185
12.2.5TWOXAR, INC. (ARIA PHARMACEUTICALS)186
12.2.6OWKIN, INC.186
12.2.7XTALPI, INC.187
12.2.8VERGE GENOMICS187
12.2.9IKTOS188
12.2.10EVAXION BIOTECH188
12.2.11STANDIGM189
12.2.12VALO HEALTH190
12.2.13BIOVISTA190
12.2.14BENCHSCI191
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.

13APPENDIX192
13.1DISCUSSION GUIDE192
13.2KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL195
13.3AVAILABLE CUSTOMIZATIONS197
13.4RELATED REPORTS197
13.5AUTHOR DETAILS198

Report Title: Artificial Intelligence ( AI ) in Drug Discovery Market by Offering (Software, Service), Technology (Machine Learning, Deep Learning), Application (Cardiovascular, Metabolic, Neurodegenerative), End User (Pharma, Biotech,CROs) - Global Forecasts ( 2022 - 2027 )


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW